Glenmark Pharmaceuticals Ltd said on Tuesday it would begin a clinical trial in India to test a combination of two antiviral drugs, favipiravir, and umifenovir, as a potential COVID-19 treatment.
Glenmark has secured Indian regulatory approval for the study, which will aim to enroll 158 hospitalized patients with moderate COVID-19, the company said.
Drugmakers across the world have been rushing to develop a treatment or vaccine for the novel coronavirus, which has infected 5.5 million people globally, killing more than 345,000, according to a Reuters tally. In India, now among the 10 most-affected nations, the death toll reached 4,167 on Tuesday.
Favipiravir is made under the brand name Avigan by Japan's Fujifilm Holdings Corp and was approved for use as an anti-flu drug there in 2014, while umifenovir is licensed as a treatment for some types of flu infections in Russia and China.
Last news about this category